intraocular pressure

Results from lantanoprostene bunod clinical studies presented at ARVOThe results of 2 clinical studies on latanosprostene bunod—CONSTELLATION and KRONUS— were presented during the Association for Research in Vision and Ophthalmology meeting last week.
Strategies for the sulcus surgeonThe iridociliary sulcus is a hidden region of the eye that provides options for optimizing patient outcomes, particularly in patients with glaucoma.
ARVO research round upThe Association for Research in Vision and Ophthalmology held its annual conference in Orlando, FL, last week and Optometry Times’ sister publication, Ophthalmology Times, was there to catch up on the latest research on glaucoma, AMD, and other diseases.
Maximum medical therapy in glaucomaA few months ago, I began to see what may be a little more progression on her OCT studies. I’m fairly confident that we’re in a good place right now as far as compliance is concerned, and I’m entering a crossroads with her regarding possibly adding therapy vs. getting a consult for a laser procedure, such as selective laser trabeculoplasty (SLT), vs. getting a cataract consult.
Ellex acquires iScience InterventionalEllex Medical Lasers Limited announced that it has recently acquired the canaloplasty business of US-based iScience Interventional, Inc.
IOP as a cornerstone to glaucoma managementThe measurement and management of intraocular pressure (IOP) in patients with glaucoma is critical. Even with the onslaught of new technologies to monitor progression and make earlier diagnoses, IOP remains a crucial data point in the optometric examination.
B+L, Nicox announce studies of glaucoma drugBausch + Lomb has initiated its phase III clinical program of latanoprostene bunod (licensed by Nicox S.A.) for the reduction of IOP in glaucoma or ocular hypertension.